Granules India Ltd. issues fresh guidance

Current mix: Peptide CDMO contributed 4% of revenue in Q1 FY27. The latest disclosed specialty-product proxy—complex generics—was 33% of total revenue in FY26, equivalent to approximately 43% of finished-dosage revenue. The company has not yet provided a Q1 FY27 update for the complex-generics share. ^{[16] [3] [2]}

Margin comparison: A precise segment-margin comparison with the legacy Paracetamol and Metformin API businesses is not disclosed. The available evidence is directional:

• Peptide CDMO: reached positive EBITDA in Q4 FY26, indicating that the newer platform had crossed into operating profitability, although no standalone margin was reported. ^[2]
• Complex/specialty generics: were identified as a driver of the improved product mix and higher gross margin; Q1 FY27 gross margin was 65.60%, up 74 basis points YoY, while EBITDA margin was 22.90%, up approximately 256 bps YoY. These are company-level margins, not specialty-product margins. ^[5]
• Legacy APIs: Paracetamol benefits from vertical integration and cost leadership, but management has also cited cost pressure and limited pricing pass-through in the legacy business. No separate Paracetamol or Metformin API EBITDA margins were reported. ^{[17] [18]}

Analyst read: The strategic shift is clearly toward higher-value, more differentiated products: CDMO is already EBITDA-positive and complex generics are expanding the mix while supporting consolidated margin improvement. However, it would be overstated to claim a quantified margin premium over Paracetamol or Metformin APIs; the disclosure supports margin accretion at the portfolio level, not a separately reported vertical-by-vertical spread.

The only explicit facility-level utilization figure is approximately 70%, for Granules’ U.S. GPI facility. Management said the facility still has substantial headroom, with additional expansion expected to be required by the end of calendar 2028. ^[5]

For the broader set of recently commissioned or expanded assets, management has not provided a separate consolidated utilization rate or a precise “peak efficiency” date. The latest guidance is qualitative: recently invested assets are still below their expected returns, and ROCE improvement should become more meaningful over the next few years as these assets move through their ramp-up phases. ^{[4] [1]}

Thus, the actionable timeline is:

• Current disclosed utilization: ~70% for GPI’s U.S. facility. ^[5]
• Capacity expansion milestone: additional GPI expansion expected by end-2028. ^[5]
• Peak operational efficiency for the overall new-asset base: no exact date guided; management indicates a multi-year ramp-up, rather than a defined peak-utilization target. ^[4]